Tetrahydrocannabinol, almost always called THC, is the molecule in cannabis responsible for getting you high. More precisely, it is a partial activator of receptors in your brain that normally respond to chemicals your own body makes, and that interaction ripples outward into everything from appetite and pain perception to mood, memory, and immune function. The compound the cannabis plant actually produces is not THC itself but an acidic precursor that only becomes psychoactive after heat transforms it. That conversion, along with the surprisingly complex way your body handles the molecule once it arrives, shapes much of what users experience and what researchers are still trying to sort out.
How the Plant Makes It
Cannabis does not produce THC directly. The living plant synthesizes an acid form called THCA (tetrahydrocannabinolic acid), which is not psychoactive. An enzyme called THCA synthase converts a shared precursor molecule, CBGA, into THCA. This enzyme was first isolated in the mid-1990s, when researchers showed that treating CBGA with an extract from young cannabis leaves generated high levels of THCA.1PubMed Central. The biosynthesis of the cannabinoids More recent microscopy work has pinpointed exactly where this happens: THCA synthase sits in the outer cell wall of disc-shaped cells in the tiny resin glands (trichomes) that coat cannabis flowers and leaves.2Current Biology. A polarized supercell produces specialized metabolites in cannabis trichomes The same precursor, CBGA, is also the starting material for CBD and CBG, which is why different cannabis strains can lean toward very different chemical profiles depending on which enzymes dominate.
THCA only becomes THC through decarboxylation, a heat-driven reaction that strips a small chemical group off the molecule. When you light a joint, bake cannabis into edibles, or vaporize flower, heat drives complete conversion of THCA into the psychoactive form.3PubMed Central. Decarboxylation Study of Acidic Cannabinoids: A Novel Approach Using Ultra-High-Performance Supercritical Fluid Chromatography/Photodiode Array-Mass Spectrometry This is why eating raw cannabis flower does almost nothing: without enough heat, the THCA stays locked in its non-psychoactive form.4Industrial & Engineering Chemistry Research. Cannabinoid Decarboxylation: A Comparative Kinetic Study
How THC Acts in the Brain
Your nervous system has its own cannabinoid signaling network, sometimes called the endocannabinoid system, that uses internally produced molecules to fine-tune neurotransmitter release. THC hijacks this system by binding to the same receptors those internal molecules target. The primary target is the CB1 receptor, which is concentrated throughout the brain, especially in areas governing memory, movement, coordination, and reward. At the molecular level, THC behaves as a partial activator of CB1 in most contexts, meaning it turns the receptor on but not as fully as some synthetic compounds do.5Frontiers in Cellular Neuroscience. Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease However, at certain nerve terminals in the hippocampus, the brain’s memory hub, THC can act as a full activator, suppressing the release of GABA, an inhibitory signaling chemical.6PubMed Central. Delta9-tetrahydrocannabinol is a full agonist at CB1 receptors on GABA neuron axon terminals in the hippocampus That suppression of GABA release in memory circuits is one reason short-term memory takes a hit while you are high.
A second receptor type, CB2, is found mainly on immune cells rather than neurons. THC and the body’s own cannabinoid, anandamide, can directly suppress immune-cell activity through CB2, and this effect can be blocked by a CB2-specific antagonist but not by a CB1 blocker.7PubMed Central. Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors CB2 signaling also plays a role in lung immunity, where it can promote certain inflammatory immune responses.8Cell Insight. Cannabinoid receptor 2 signal promotes type 2 immunity in the lung The dual nature of cannabinoid receptors, one type concentrated in the brain and another on immune cells, helps explain why THC has such a wide range of effects beyond just making you feel high.
What Happens After You Consume It
How you take THC dramatically changes the experience, largely because of what your liver does with it. When you eat an edible, THC passes through the digestive tract and into the liver before reaching general circulation. There, liver enzymes, primarily one called CYP2C9, convert THC into a metabolite called 11-hydroxy-THC (11-OH-THC).9PubMed Central. Hepatic Enzymes Relevant to the Disposition of (-)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC This metabolite is actually more psychoactive than THC itself, and blood levels of 11-OH-THC are higher after eating cannabis than after smoking it.10ScienceDirect (Current Opinion in Food Science). Cannabis edibles: dosing, encapsulation, and stability considerations That is a big part of why edibles can feel so much more intense and last so much longer than smoking: you are essentially getting a double dose of psychoactivity, the original THC plus a more potent metabolite generated by first-pass liver processing.
CYP2C9 handles an estimated 70 to 80 percent of THC breakdown, though CYP2C19 and CYP3A also contribute and can generate additional metabolites.11PubMed Central. CYP2C9, CYP3A and CYP2C19 metabolize Δ9-tetrahydrocannabinol to multiple metabolites but metabolism is affected by human liver fatty acid binding protein (FABP1) Genetic variations in these enzymes differ across individuals, which is one reason the same dose of an edible can floor one person and barely register for another.
THC is also highly fat-soluble, so it accumulates in body fat over time with repeated use.12PubMed Central. Reintoxication: the release of fat-stored delta(9)-tetrahydrocannabinol (THC) into blood is enhanced by food deprivation or ACTH exposure This storage is why THC metabolites show up on drug tests long after the last use, sometimes weeks later for heavy users. Animal research has even shown that fasting or stress hormones can mobilize stored THC back into the bloodstream from fat tissue, a finding that raises interesting questions about whether very heavy users might experience low-level re-exposure during periods of rapid weight loss or high stress.
Medical Uses
THC-based medications have been approved in various forms for decades, though the medical cannabis landscape remains a patchwork of federal restrictions and state-level access. The U.S. FDA approved two synthetic cannabinoid drugs, dronabinol and nabilone, back in 1985 for chemotherapy-induced nausea and vomiting that did not respond to standard treatments.13PubMed. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting These drugs work by activating CB1 and CB2 receptors in areas of the brain that control nausea.14PubMed Central. A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting Dronabinol also carries an approval for appetite stimulation in people with AIDS-related wasting.
The appetite-stimulating effect of THC connects to a fascinating loop between cannabinoid receptors and the hunger hormone ghrelin. In a pilot study of HIV-positive men, cannabis administration increased ghrelin levels by about 42 percent compared to a decrease with placebo, and higher THC exposure correlated with larger ghrelin increases.15PubMed Central. A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men Separate research in mice showed that ghrelin’s ability to stimulate food intake requires a functioning CB1 receptor, and that blocking CB1 eliminated ghrelin’s appetite-boosting effects entirely.16PLoS ONE. The Orexigenic Effect of Ghrelin Is Mediated through Central Activation of the Endogenous Cannabinoid System In other words, the body’s own hunger signaling and the cannabinoid system are wired together, which is why “the munchies” are not just a cultural joke but a real pharmacological effect.
Pain management is another major area of interest. Animal studies have found that combining a cannabinoid with morphine can produce synergistic pain relief, potentially allowing lower opioid doses. The analgesic boost appears to work through CB1 receptors in some pain models and CB2 in others.17PubMed Central. Opioid-sparing effects of cannabinoids on morphine analgesia: participation of CB(1) and CB(2) receptors Whether this translates cleanly to human chronic-pain management is still being worked out, but the concept of using cannabinoids to reduce opioid dosing has drawn significant clinical attention given the ongoing opioid crisis.
Psychiatric and Brain-Development Risks
The link between heavy THC use and psychotic disorders has become one of the most studied and most debated topics in cannabis research. A case-control study in south London found that people who used high-potency cannabis (the kind commonly called “skunk”) daily were more than five times as likely to be diagnosed with a psychotic disorder compared to people who never used cannabis.18The Lancet. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study An earlier study found that among cannabis users, those who preferred high-potency varieties had nearly seven times the odds of a psychosis diagnosis compared to users of lower-potency forms.19PubMed Central. High-potency cannabis and the risk of psychosis These are observational findings, so they do not prove that THC alone causes psychosis; people predisposed to psychosis might also be drawn to heavier cannabis use. But the dose-response pattern, where more frequent use of stronger material carries higher risk, is consistent across multiple studies and hard to dismiss entirely.
The adolescent brain appears especially vulnerable. Neuroimaging research on teenage cannabis users has found alterations in cortical thickness across several brain regions, with changes related to both how heavily someone used and how young they started.20PubMed Central. Effects of Cannabis on the Adolescent Brain Animal studies have added a mechanistic layer to this picture. In adolescent female rats, THC exposure disrupted the endocannabinoid system’s normal developmental processes in the prefrontal cortex, altered the composition of receptor proteins at synapses, and impaired cognition in adulthood. The researchers concluded that vulnerability to lasting THC effects during adolescence resides partly in the disruption of the role the endocannabinoid system itself plays in brain maturation.21PubMed. Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortex The endocannabinoid system is not just a target for the drug; it is an active participant in pruning and refining brain circuits during the teenage years, and flooding it with THC throws that process off track.
Cannabis Hyperemesis Syndrome
One of the stranger consequences of heavy, long-term THC use is cannabis hyperemesis syndrome (CHS), a condition marked by severe, recurring episodes of nausea and vomiting. The irony is hard to miss: THC is prescribed as an anti-nausea drug, yet in some chronic users it causes exactly the opposite. This biphasic behavior, anti-nausea at lower doses but pro-nausea at high chronic doses, seems to be central to the syndrome.22PubMed Central. Cannabis hyperemesis syndrome: an update on the pathophysiology and management A systematic review of CHS cases found that virtually all patients reported at least weekly cannabis use, about 85 percent had abdominal pain, and a striking 92 percent found temporary relief from compulsive hot showers or baths, a hallmark symptom that often helps clinicians distinguish CHS from other causes of vomiting.23PubMed Central. Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review
CHS is distinct from cannabis withdrawal syndrome, even though both involve nausea and vomiting. CHS happens while someone is still using cannabis and gets worse with continued use; withdrawal syndrome happens after stopping.24PubMed Central. Cannabinoid hyperemesis syndrome and cannabis withdrawal syndrome: a review of the management of cannabis-related syndrome in the emergency department The only reliable cure for CHS is quitting cannabis entirely, and about 97 percent of documented cases saw symptoms resolve after stopping.25PubMed Central. Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review Emergency departments in states with legal cannabis have reported rising CHS presentations, and it remains underdiagnosed because many clinicians and patients are not yet aware of it.
Tolerance and How the Brain Recovers
With regular use, the brain adapts to constant THC exposure by pulling CB1 receptors off the surface of neurons, a process called downregulation. Brain imaging of chronic daily cannabis users showed that CB1 receptor availability was roughly 15 to 20 percent lower than in non-users, particularly in the cortex and limbic regions tied to emotion and memory.26PubMed Central. Reversible and regionally selective downregulation of brain cannabinoid CB 1 receptors in chronic daily cannabis smokers This reduced receptor density is the biological basis of tolerance: the same dose produces less effect because there are fewer receptors available to activate.
The encouraging news is that this process appears largely reversible. In one imaging study, the group differences in CB1 receptor availability between chronic users and non-users were no longer detectable after just two days of abstinence, and remained normalized at 28 days.27PubMed Central. Rapid Changes in CB1 Receptor Availability in Cannabis Dependent Males after Abstinence from Cannabis A separate study confirmed that receptor levels increased specifically in the regions that had been depleted, returning toward baseline after roughly four weeks off cannabis, though the hippocampus was an exception and showed slower recovery.28PubMed Central. Reversible and regionally selective downregulation of brain cannabinoid CB 1 receptors in chronic daily cannabis smokers During early abstinence, lower CB1 availability correlated with more severe withdrawal symptoms, which fits the picture: fewer functioning receptors means the brain’s own endocannabinoid signaling is impaired, producing irritability, insomnia, and anxiety until the receptors bounce back.29PubMed Central. The cannabis withdrawal syndrome: current insights
There may be sex differences in this recovery process. A rat study found that while CB1 receptors in the hippocampus bounced back in most subregions after two weeks without THC, females showed persistent reductions in more areas than males did.30PubMed Central. Sex-specific alterations in hippocampal cannabinoid 1 receptor expression following adolescent delta-9-tetrahydrocannabinol treatment in the rat This is still animal data, but it aligns with broader clinical observations that women and men often differ in their patterns of cannabis dependence and withdrawal.31PubMed Central. Cannabis Withdrawal: A Review of Neurobiological Mechanisms and Sex Differences
Delta-8 THC and the Isomer Question
When people say “THC,” they almost always mean delta-9-THC, the dominant psychoactive form. But delta-8-THC has surged in popularity, partly because it can be synthesized from hemp-derived CBD and has existed in a legal gray zone. Structurally, the two molecules differ only in the position of a single double bond: between carbons 8 and 9 in delta-8, versus carbons 9 and 10 in delta-9. That small shift gives delta-8 a lower affinity for the CB1 receptor, resulting in weaker psychoactive effects.32PubMed Central. Delta-8-THC: Delta-9-THC’s nicer younger sibling? Users often describe delta-8 as producing a milder, less anxiety-prone high, though controlled clinical data remain thin. The bigger concern with delta-8 products is manufacturing quality: converting CBD to delta-8 involves chemical reactions that can leave behind unknown byproducts, and these products are not subject to the same testing requirements as regulated cannabis in legal markets.
The Entourage Effect Debate
A common claim in the cannabis world is that whole-plant products work better than pure THC because of the “entourage effect,” the idea that terpenes, flavonoids, and minor cannabinoids all synergize with THC and CBD to produce superior therapeutic results. The concept is appealing and widely marketed, but the evidence behind it remains surprisingly thin. A comprehensive review found that while exploratory research suggests terpenes can influence cannabinoid activity, the potential for synergistic or additive enhancement remains unproven, and further clinical trials are needed.33PubMed Central. The Entourage Effect in Cannabis Medicinal Products: A Comprehensive Review A narrative scoping review reached a similar conclusion: limited evidence supports the entourage effect as a stable, predictable phenomenon, and there is not enough data to base clinical recommendations or product regulation on the hypothesis.34PubMed. Does the “Entourage Effect” in Cannabinoids Exist? A Narrative Scoping Review
None of this means the entourage effect is definitively false. It means the marketing has outrun the science. Many people report subjective differences between whole-plant cannabis and isolated THC, and there is biological plausibility for interactions among the hundreds of compounds in the plant. But “plausible and reported anecdotally” is different from “proven in controlled settings,” and consumers should be skeptical of product labels that invoke the entourage effect as though it were settled science.
THC and Driving Impairment
One of the thorniest practical problems around THC is measuring impairment for driving. Unlike alcohol, where blood concentration tracks fairly well with how impaired you are, THC blood levels correlate poorly with actual driving performance. A report to the U.S. Congress noted this weak correlation and concluded that setting a per se legal limit for THC in the blood, the way we set 0.08 percent for alcohol, is not scientifically meaningful.35ROSA P. Marijuana-Impaired Driving – A Report to Congress THC can linger in the blood long after impairment has worn off, especially in frequent users, meaning a positive blood test does not necessarily mean a driver was high at the time. Conversely, occasional users can be significantly impaired at blood levels that fall below proposed thresholds. This mismatch has made cannabis-impaired driving laws far more complicated to craft and enforce than drunk-driving laws.
Prenatal Exposure
Cannabis use during pregnancy has been climbing, sometimes driven by the perception that it is a natural remedy for morning sickness. The research on prenatal THC exposure, while still evolving, offers several reasons for caution. Human and animal studies have found that prenatal cannabis exposure influences brain development and can have lasting effects on cognitive function.36PubMed Central. Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain In a primate study using rhesus macaques, all THC-exposed fetal brains showed signs of damage that were absent in controls, including indicators of reduced blood flow in the cerebellum and evidence of white-matter injury in the temporal and parietal lobes.37Scientific Reports. Prenatal delta-9-tetrahydrocannabinol exposure alters fetal neurodevelopment in rhesus macaques
A human study that tracked DNA methylation, the chemical tags cells use to turn genes on or off, found that prenatal cannabis exposure was associated with altered methylation at genes involved in neurodevelopment. These changes were detectable not only at birth but persisted at ages 7, 15, and 27.38Molecular Psychiatry. Prenatal cannabis exposure is associated with alterations in offspring DNA methylation at genes involved in neurodevelopment, across the life course The affected gene pathways involved neurotransmission, neural structure, and pathways associated with neurodevelopmental disorders. Whether these methylation changes translate into clinically meaningful outcomes for every exposed child is still being studied, but the biological signal is real and consistent enough that major medical organizations advise against cannabis use during pregnancy.